大会日程（7月15日第一天）
PROGRAM FOR BEST OF ASCO IN CHINA 2011（DAY 1）
| July 15, 2011 Day 1 | ||
| Time | Session | Speaker |
| 8:00–8:15 | Opening speech on behalf of CSCO Opening speech on behalf of ASCO | 莫树锦(Tony Mok) David Goldstein |
| Gastro–intestinal Cancer Session 1 Chair: 李 进(Jin Li) | ||
| 8:15–8:40 | 3503 The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R–04. | 王理伟(Liwei Wang) |
| 3504 Capecitabine (Cap) vs 5-fluorouracil (5-FU)–based (neo) adjuvant chemo radiotherapy (CRT) for locally advanced rectal cancer (LARC): Long term results of a randomized phase III trial. | ||
| 3507 The efficacy of oxalipatin (Ox) when added to 5-flurorouracil/leucovorin (FU/L) in stage II colon cancer. | ||
| 8:40–8:50 | Discussion Topic: What is the standard adjuvant therapy for resectable colorectal cancer | 徐建明(Jianming Xu) |
| 8:50–8:55 | Q & A | 李 进(Jin Li)) 徐建明(Jianming Xu) 王理伟(Liwei Wang |
| Gastro–intestinal Cancer Session 2 Chair: 沈 琳 (Lin Shen) | ||
| 8:55–9:20 | 3535 Primary colorectal tumors and their metastasis are genetically not the same Implications for choice of targeted treatment? | 李 进 (Jin Li) |
| 3510 Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first line metastatic colorectal cancer (mCRC). | ||
| 3511 Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first line chemotherapy with or without cetuximab. | ||
| 9:20–9:35 | Discussion Topic: Genomic selection for targeted therapy in colorectal cancer | David Goldstein 翻译：陈 功(Gong Chen) |
| 9:35–9:40 | Q & A | 沈 琳 (Lin Shen) David Goldstein 李 进(Jin Li) |
| 9:40–9:50 | Break | |
| Gastro–intestinal Cancer Session 3 Chair: 徐建明(Jianming Xu) | ||
| 9:50–10:10 | 4003 Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GeJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5FU (ECF) before and after CI 5FU and radiotherapy (CRT) compared to bolus 5FU/LV before and after CRT: Intergroup trail CALGB 20101. | 沈 琳 (Lin Shen) |
| 4004 A multi center, randomized phase III trial comparing second line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC). | ||
| 10:10–10:25 | LBA4002 Adjuvant capecitabine and oxaliplatin for gastric cancer: Results of the Phase III CLASSIC trial. | Yung-Jue Bang 翻译：张小田(Xiaotian Zhang) |
| 10:25–10:40 | Discussion Topic: What is the standard adjuvant therapy for resectable gastric cancer | Yung-Jue Bang 翻译：张小田(Xiaotian Zhang) |
| 10:40–10:45 | Q & A | 徐建明(Jianming Xu) Yung-Jue Bang, 沈 琳(Lin Shen) |
| Gastro–intestinal Cancer Session 4 Chair: 王杰军(Jiejun Wang) | ||
| 10:45–10:55 | 4001 Global investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of tts Treatment with Sorafenib (GIDEON) second interim analysis in more than 1,500 patients: Clinical findings in patients with liver dysfunction. | 潘宏铭(Hongming Pan) |
| 10:55–11:05 | Discussion Topic: Is sorafenib indicated in all patients with unresectable HCC? | 秦叔逵(Shukui Qin) |
| 11:05–11:10 | Q & A | 王杰军(Jiejun Wang), 秦叔逵(Shukui Qin), 潘宏铭(Hongming Pan) |
| Genitounrinary Cancer Session Chair: 郭 军(Jun Guo) | ||
| 11:10–11:30 | 4516 Cabozantiinib (XL184) in metastatic castration resistant prostate cancer (mCRPC): Results from a phase 2 randomized discontinuation trail. | 叶定伟 (Dingwei Ye) |
| LBA4517 Evaluation of circulating tumor cell (CTC) enumeration as an efficacy. response biomarker of overall survival (OS) in metastatic castration resistant prostate cnacer (mCRPC): Planned final analysis (FA) of COU “AA” 301, a randomized double blind placebo controlled phase 3 study of abiraterone acetate (AA) plus low dose prednisone (P) post docetaxel. | ||
| 11:30–11:40 | 4503 Axitinib vs sorafenib as second line therapy for metastatic renal cell carcinoma (mRCC): Results of phase 3 AXIR trial. | 郭 军(Jun Guo) |
| 11:40–11:50 | Discussion Topic: Standard therapy for hormone resistant prostate cancer | 叶定伟 (Dingwei Ye) |
| 11:50–11:55 | Q & A | 叶定伟 (Dingwei Ye) 郭 军(Jun Guo) |
| 11:55–14:00 | Lunch and/or satellite symposium | |
| Head and Neck Session Chair: 张 力(Li Zhang) | ||
| 14:00–14:20 | 5500 A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III–IV head and neck squamous cell carcinoma (HNC). | 郭 晔(Ye Guo) |
| 5501 Sequential chemoradiotherapy (SCRT) for a larynx preservation (LP): Results of the randomized phase II TREMPLIN study. | ||
| 14:20–14:30 | Discussion Topic: The role of cetuximab in H&N cancer | 张 力(Li Zhang) |
| 14:30–14:35 | Q & A | 张 力(Li Zhang), 郭 晔(Ye Guo) |
| Melanoma Session Chair: 梁 军(Jun Liang) | ||
| 14:35–14:55 | 8509 Melanoma BRIM 2: An open label, multicenter phase II study of RG7204 (PLX4032) in previously Treated patients with BRAF V600T mutation positive metastatic melanoma. | 郭 军(Jun Guo) |
| LBA4 Melanoma Phase III randomized, open label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF mutated melanomas. | ||
| 14:55–15:05 | Discussion Topic: BRAF inhibition for melanoma | 郭 军(Jun Guo) |
| 15:05–15:10 | Q & A | 梁 军(Jun Liang) 郭 军(Jun Guo) |
| Lymphoma session Chair: 马 军(Jun Ma) | ||
| 15:10–15:35 | 8000 R CHOP14 vs R CHOP 21: Result of a randomized phase III trail for the treatment of patients with newly diagnosed diffuse large B cell non Hodgkin’s Lymphoma. | 朱 军(Jun Zhu) |
| 8001 Randomized phase III US/Canadian intergroup trial (SWOG S9704) comparing CHOP±R x 8 to CHOP±R x 6 followed by autotransplant for patients with high intermediate (H Int) or high B grade diffuse aggressive non Hodgkin’s Lymphoma (NNL). | ||
| 8004 Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B cell Lymphoma (DLBCL): CORAL final analysis. | ||
| 15:35–15:45 | Discussion Topic: Current standard therapy for diffuse large B–cell NHL | 马 军(Jun Ma) |
| 15:45–15:50 | Q & A | 马 军(Jun Ma), 朱 军(Jun Zhu) |
| 15:50–16:00 | Break | |
| Gynecologic malignancy Session Chair: 吴令英(Lingying Wu) | ||
| 16:00–16:20 | 5003 Phase II randomized placebo controlled study of olaparib (AZD2281) in patients with platinum sensitive relapsed serous ovarian cancer (PSR SOC). | 吴小华(Xiaohua Wu) |
| LBA5007 Chemotherapy with or without bevacizumab (BEV) in patients with platinum sensitive ovarian cancer. | ||
| 16:20–16:30 | Discussion Topic: The role of anti–angiogenesis in ovarian cancer | 吴令英(Lingying Wu) |
| 16:30–16:35 | Q & A | 吴令英(Lingying Wu), 吴小华(Xiaohua Wu) |
| Current Standard Practice after ASCO 2011 Chair: | ||
| 16:35–17:15 | Chemotherapy and target therapy progression of Gastric Cancer | Yung-Jue Bang 翻译：张小田(Xiaotian Zhang) |
| 17:15–17:55 | Chemotherapy and target therapy progression of Colon Cancer | David Goldstein 翻译：陈 功(Gong Chen) |
| 17:55–19:30 | Buffet Dinner | |
| 19:00–20:30 | Satellite symposium | |
编辑: riset 作者:丁香园通讯员
以下网友留言只代表网友个人观点，不代表网站观点
